Updates are available Correction dated 2024-08-29

Article History

Received: 22 May 2024

Accepted: 26 June 2024

First Online: 15 July 2024

Change Date: 29 August 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13300-024-01633-3

Declarations

:

: Zhikai Feng, Guoliang Chen, Jing Fu, Shan Gao, Hongyan Zhang, Zicai Liang, and Li-Ming Gan are employees of Suzhou Ribo Life Science Co. Ltd. Erin Morgan and Sanjay Bhanot are employees of Ionis Pharmaceuticals, Inc. (the original company name was ISIS Pharmaceuticals, Inc.). Linong Ji reports receiving consulting and lecture fees from Eli Lilly and Company, Novo Nordisk, Merck, Bayer, Sanofi–Aventis, Roche, Merck Sharp & Dohme, Metronics, AstraZeneca, Boehinger Ingelheim, and Abbott. Leili Gao has nothing to disclose.

: The trial was conducted in accordance with the 2013 Declaration of Helsinki and the International Conference on Harmonization’s Good Clinical Practice guidelines, and it was approved by the institutional review board of Peking University People's Hospital (the main center; approval number: 2019PHA018-001) and the relevant institutional review board at each study site. A list of the IECs/IRBs that reviewed and approved the protocol are provided in Supplemental Table S2. Informed consent was obtained from all participants prior to enrollment in the study.